DXCM241220C125000
- 0.05
- 0.000.00%
DexCom Newsroom
Oura Raises $200M With Investment From Dexcom
Oura Boosts Valuation to $5.2B in Latest Funding Round
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
AI-Driven Glucose Biosensing: Dexcom's (DXCM) Path To A Comeback
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $150
Dexcom's Over-the-counter Glucose Monitor Now Offers Users an AI Summary of How Sleep, Meals and More Impact Sugar Levels
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
Express News | Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (Cgm) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 Cgm
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
Is Dexcom, Inc. (DXCM) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Worst Performing Stocks for Tax Loss Selling – Wolfe
Peering Into DexCom's Recent Short Interest
The Nasdaq 100 is about to adjust, and these 11 companies may see a 50% increase in upside potential.
As the annual adjustment of the NASDAQ 100 Index approaches, a group of potential stocks is preparing to make their debut. This adjustment not only brings prestige to these companies but may also trigger a large-scale inflow of capital, further driving up stock prices.
DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher
TNDM Stock to Gain From T:slim X2 With Dexcom G7 Launch in Canada
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
Why DexCom, Inc. (NASDAQ:DXCM) Looks Like A Quality Company
Nephron Research Adjusts Price Target on DexCom to $125 From $145
DexCom Is Maintained at Buy by Citigroup